...
首页> 外文期刊>European Journal of Nuclear Medicine and Molecular Imaging >(111)In)DOTATOC as a dosimetric substitute for kidney dosimetry during ((90)Y)DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach.
【24h】

(111)In)DOTATOC as a dosimetric substitute for kidney dosimetry during ((90)Y)DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach.

机译:(111)In)DOTATOC作为((90)Y)DOTATOC治疗期间肾脏剂量学的剂量学替代品:伽玛相机/探头组合方法的结果和评估。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: During [(90)Y]DOTATOC therapy, for determination of kidney doses a conventional approach using co-injected [(111)In]DOTATOC was evaluated for validity, reliability and reproducibility as well as for the influence of methodological variations and bremsstrahlung. Biologically effective doses were estimated by calculating the relative effectiveness (RE) of kidney doses. METHODS: Fractionated [(90)Y]DOTATOC therapy (n=20 patients, 3.1+/-0.7 GBq/therapy cycle, 45 therapy cycles) included co-injection of 157+/-37 MBq [(111)In]DOTATOC and a nephroprotective infusion regimen. From serial gamma camera/probe measurements, individual region of interest (ROI) sets were established and kidney doses were determined according to MIRDOSE3 (corrected for individual kidney mass) by use of three methodological variants: (1) correction for interfering organs (liver/spleen) and background activity, (2) correction for interfering organs alone and (3) no corrections. A phantom study was performed with (111) In aloneand with (111)In +(90)Y to estimate the influence of (90)Y bremsstrahlung. RESULTS: Mean kidney dose (method 1, n=20 patients, 20 therapy cycles) was 1.51+/-0.60 Gy/GBq [(90)Y]DOTATOC (1.41+/-0.48 Gy/GBq for n=20 patients, 45 therapy cycles). With partial correction (method 2) or no correction (method 3) for interfering activity, kidney doses increased significantly, to 2.71+/-1.26 Gy/GBq and 3.15+/-1.22 Gy/GBq, respectively. The span of REs ranged from 1.02 to 1.24. Inter-observer variability was as high as +/-32% (+/-2SD). (90)Y bremsstrahlung accounted for a 4-11% underestimation of obtained target activity. CONCLUSION: The obtained kidney doses are highly influenced by methodological variations. Full correction for interfering activity clearly underestimates kidney doses. By comparison, (90)Y bremsstrahlung and variability in the relative effectiveness of kidney doses cause minor bias. Inter-observer variability must be considered when interpreting kidney doses.
机译:目的:在[(90)Y] DOTATOC治疗期间,为了确定肾脏剂量,评估了使用共注射[[111)In] DOTATOC的常规方法的有效性,可靠性和可重复性,以及方法变化和致的影响。 。通过计算肾脏剂量的相对有效性(RE)估算生物有效剂量。方法:分次[[90)Y] DOTATOC治疗(n = 20例患者,3.1 +/- 0.7 GBq /治疗周期,45个治疗周期)包括共注射157 +/- 37 MBq [(111)In] DOTATOC和肾保护性输注方案。通过连续的伽马相机/探头测量,建立了单个目标区域(ROI)集,并通过使用三种方法学变体根据MIRDOSE3(针对单个肾脏质量进行了校正)确定了肾脏剂量:(1)校正干扰器官(肝脏/脾脏和背景活动,(2)仅对干扰器官进行矫正,(3)不进行矫正。对(111)In单独使用(111)In +(90)Y进行了幻像研究,以估计(90)Y ms致辐射的影响。结果:平均肾脏剂量(方法1,n = 20名患者,20个治疗周期)为1.51 +/- 0.60 Gy / GBq [(90)Y] DOTATOC(n = 20患者,1.41 +/- 0.48 Gy / GBq,45治疗周期)。通过对干扰活性进行部分校正(方法2)或不进行校正(方法3),肾脏剂量显着增加,分别达到2.71 +/- 1.26 Gy / GBq和3.15 +/- 1.22 Gy / GBq。 RE的范围为1.02至1.24。观察者之间的变异性高达+/- 32%(+/- 2SD)。 (90)致辐射造成的目标活动低估了4-11%。结论:所获得的肾脏剂量受到方法学差异的高度影响。完全纠正干扰活性显然低估了肾脏剂量。相比之下,(90)Y ms致辐射和肾脏剂量相对有效性的差异会引起较小的偏倚。解释肾脏剂量时,必须考虑观察者之间的差异。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号